Strategic Plan: Research
Strategic Plan: Research
1.1 Develop the mechanistic understanding, technology, and translational strategies to find treatments for all human diseases
Support and create expert-led technology centers (instrumentation and people) to lower access barriers to methodological innovations and to accelerate groundbreaking research.
Progress to 2024:
Small Molecule Discovery Center – Charles Hart, new director.
NMR structure determination and drug discovery accelerated by new AI methods.
Build and grow collaborative teams to work on cross-cutting challenges that bridge the gap from atoms to organisms and populations.
Progress to 2024:
DARPA grant for anesthesia innovation (Shoichet, Sello, Manglik, Irwin, Basbaum, Hibbs).
Center for Collaborative Innovation (CCI): collaboration event, MAKK grants (Guo).
QBI collaborative opportunities: multiple RFAs throughout the year, including QCRG (infectious disease), UCD (drug/drug target discovery), CCMI (cancer).
Build teams to integrate discovery, translational pharmacology and regulatory science to develop new therapeutic agents and modalities.
Establish drug-focused research as a pillar of the campus precision medicine initiative
Support and create expert-led technology centers (instrumentation and people) to lower access barriers to methodological innovations and to accelerate groundbreaking research.
Progress to 2024:
- Small Molecule Discovery Center – Charles Hart, new director.
- NMR structure determination and drug discovery accelerated by new AI methods.
Build and grow collaborative teams to work on cross-cutting challenges that bridge the gap from atoms to organisms and populations.
Progress to 2024:
DARPA grant for anesthesia innovation (Shoichet, Sello, Manglik, Irwin, Basbaum, Hibbs).
Center for Collaborative Innovation (CCI): collaboration event, MAKK grants (Guo).
QBI collaborative opportunities: multiple RFAs throughout the year, including QCRG (infectious disease), UCD (drug/drug target discovery), CCMI (cancer).
Build teams to integrate discovery, translational pharmacology and regulatory science to develop new therapeutic agents and modalities.
Establish drug-focused research as a pillar of the campus precision medicine initiative
Optimize health and care delivery through clinical and health services research affecting medications, tests, devices and delivery innovations.
1. Create and support collaborations that assess the clinical effectiveness, preferences, cost-effectiveness, budget impact, and health equity impact of health technologies to inform appropriate and efficient use to achieve optimal health outcomes.
Progress to 2024:
Preclinical design and clinical translation of TB regimens (PReDicTR) Consortium (Savic).
Natl Academy Med Committee: Strategies to align investments in innovations for therapeutic disease burden and unmet needs (Phillips).
Health equity study that determined the clinical validity of understudied candidate functional SLCO1B1 variants common in understudied groups. (Oni-Orisan and collaborators at UCSF, Stanford and Kaiser).
2. Create and support collaborations that assess health policies, access to health technologies, quality of care, cost, the relationship between quality and cost, and the impact on health outcomes.
Create and support collaborations that assess the clinical effectiveness, preferences, cost-effectiveness, budget impact, and health equity impact of health technologies to inform appropriate and efficient use to achieve optimal health outcomes.
Progress to 2024:
Preclinical design and clinical translation of TB regimens (PReDicTR) Consortium (Savic).
Natl Academy Med Committee: Strategies to align investments in innovations for therapeutic disease burden and unmet needs (Phillips).
Health equity study that determined the clinical validity of understudied candidate functional SLCO1B1 variants common in understudied groups. (Oni-Orisan and collaborators at UCSF, Stanford and Kaiser).
Create and support collaborations that assess health policies, access to health technologies, quality of care, cost, the relationship between quality and cost, and the impact on health outcomes.